Reopro and Coagulation time abnormal - a phase IV clinical study of FDA data

Summary:

Coagulation time abnormal is reported only by a few people who take Reopro.

The phase IV clinical study analyzes which people take Reopro and have Coagulation time abnormal. It is created by eHealthMe based on reports of 4,780 people who have side effects while taking Reopro from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Jan, 29, 2023

4,780 people reported to have side effects when taking Reopro.
Among them, 3 people (0.06%) have Coagulation time abnormal.

What is Reopro?

Reopro has active ingredients of abciximab. eHealthMe is studying from 4,782 Reopro users for its effectiveness, alternative drugs and more.

What is Coagulation time abnormal?

Coagulation time abnormal is found to be associated with 186 drugs and 111 conditions by eHealthMe.

Number of Reopro and Coagulation time abnormal reports submitted per year:

Could Reopro cause Coagulation time abnormal?

Time on Reopro when people have Coagulation time abnormal *:

Gender of people who have Coagulation time abnormal when taking Reopro *:

female: 0.0 %
male: 100 %

Age of people who have Coagulation time abnormal when taking Reopro *:

Common drugs people take besides Reopro *:

Angiomax: 3 people, 100.00%
Versed: 1 person, 33.33%
Heparin: 1 person, 33.33%
Fentanyl: 1 person, 33.33%

Common side effects people have besides Coagulation time abnormal *:

Vascular Access Complication: 1 person, 33.33%
Thrombosis (formation of a blood clot inside a blood vessel): 1 person, 33.33%
Pulmonary Haemorrhage (acute bleeding from the lung): 1 person, 33.33%
Procedural Pain: 1 person, 33.33%
Pain: 1 person, 33.33%
Infusion Site Extravasation (flow of (blood or lymph) from infusion site): 1 person, 33.33%
Haemorrhage (bleeding): 1 person, 33.33%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 1 person, 33.33%
Drug Ineffective: 1 person, 33.33%
Drug Administration Error: 1 person, 33.33%

Common conditions people have *:

Percutaneous Coronary Intervention: 2 people, 66.67%

* Approximation only. Some reports may have incomplete information.

Do you take Reopro and have Coagulation time abnormal?

Check whether Coagulation time abnormal is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Coagulation time abnormal and when was it recovered:

Coagulation time abnormal in Reopro

Expand to all the drugs that have ingredients of abciximab:

Coagulation time abnormal and drugs with ingredients of abciximab

Alternative drugs to, pros and cons of Reopro:

Reopro (4,782 reports)

Common Reopro side effects:

Browse all side effects of Reopro:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Coagulation time abnormal treatments and more:

Coagulation time abnormal (327 reports)

COVID vaccines that are related to Coagulation time abnormal:

Common drugs associated with Coagulation time abnormal:

Angiomax: 140 reports

All the drugs that are associated with Coagulation time abnormal:

Coagulation time abnormal (186 drugs)

All the conditions that are associated with Coagulation time abnormal:

Coagulation time abnormal (111 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on abciximab (the active ingredients of Reopro) and Reopro (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.